Oral Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ORL015 MIFTS: 49	Oral Squamous Cell Carcinoma Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Oral Squamous Cell Carcinoma

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma ¹¹ ¹⁹ ⁷⁵ ¹⁴ ¹⁶

Squamous Cell Carcinoma of Mouth ⁷¹

Mouth Squamous Cell Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050866

EFO ¹⁶ EFO_0000199

UMLS ⁷¹ C0585362

Sources

Summaries for Oral Squamous Cell Carcinoma

GARD: ¹⁹ A squamous cell carcinoma arising from the oral cavity. It affects predominantly adults in their fifth and sixth decades of life and is associated with alcohol and tobacco use. Human papillomavirus is present in approximately half of the cases. It is characterized by a tendency to metastasize early to the lymph nodes. When the tumor is small, patients are often asymptomatic. Physical examination may reveal erythematous or white lesions or plaques. The majority of patients present with signs and symptoms of locally advanced disease including mucosal ulceration, pain, difficulty with speaking, chewing, and swallowing, bleeding, weight loss, and neck swelling. Patients may also present with swollen neck lymph nodes without any symptoms from the oropharyngeal tumor. The most significant prognostic factors are the size of the tumor and the lymph nodes status.

MalaCards based summary: Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and tongue squamous cell carcinoma. An important gene associated with Oral Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is ncRNAs involved in STAT3 signaling in hepatocellular carcinoma. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, myeloid and skin.

Disease Ontology: ¹¹ An oral cavity cancer that has material basis in squamous cells.

Wikipedia: ⁷⁵ Squamous-cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Sources

Related Diseases for Oral Squamous Cell Carcinoma

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	33.7	UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
2	tongue squamous cell carcinoma	32.0	UCA1 MIR21 MIR193A MALAT1
3	tongue carcinoma	31.9	MIR21 MIR100 MALAT1
4	esophageal cancer	31.8	UCA1 MIR21 MIR193A MIR100 MALAT1 HOTAIR
5	melanoma	31.8	UCA1 MIR21 MIR193A MIR137 MIR100 MALAT1
6	ovarian cancer	31.6	UCA1 TUG1 NEAT1 MIR21 MIR193A MIR100
7	lung cancer susceptibility 3	31.6	TUG1 MIR21 MIR193A MALAT1 HOTAIR H19
8	esophagus squamous cell carcinoma	31.6	TUG1 MALAT1 HOTAIR CCAT1
9	lung cancer	31.6	UCA1 TUG1 NEAT1 MIR21 MIR193A MIR137
10	nasopharyngeal carcinoma	31.5	NEAT1 MIR21 MIR193A MIR100 MALAT1 HOTAIR
11	hepatocellular carcinoma	31.5	UCA1 TUG1 NEAT1 MIR21 MIR193A MIR137
12	pancreatic cancer	31.2	UCA1 TUG1 NEAT1 MIR21 MIR100 MALAT1
13	retinitis pigmentosa 11	31.2	UCA1 TUG1 NEAT1 MIR193A HOTAIR CCAT2
14	pancreatic ductal adenocarcinoma	31.2	UCA1 MIR21 MIR193A MALAT1 HOTAIR H19
15	leukemia, acute myeloid	31.2	UCA1 TUG1 MIR21 MIR193A MALAT1 HOTAIR
16	cervical cancer	31.2	UCA1 TUG1 NEAT1 MIR21 MIR193A MALAT1
17	gastric cancer	31.1	UCA1 TUG1 NEAT1 MIR21 MALAT1 LINC00668
18	osteogenic sarcoma	31.1	UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
19	bladder cancer	31.1	UCA1 TUG1 MIR21 MIR100 MALAT1 HOTAIR
20	endometrial cancer	31.1	UCA1 TUG1 NEAT1 MIR21 MIR193A HOTAIR
21	kidney cancer	31.0	MIR21 MIR193A MALAT1 HOTAIR H19
22	pharynx cancer	31.0	MIR21 MIR193A MIR100
23	laryngeal squamous cell carcinoma	30.8	NEAT1 MIR21 MALAT1 HOTAIR H19 CCAT1
24	thyroid carcinoma	30.8	UCA1 NEAT1 MALAT1 HOTAIR H19
25	thyroid cancer, nonmedullary, 1	30.8	NEAT1 MALAT1 HOTAIR H19
26	lung squamous cell carcinoma	30.7	TUG1 MIR193A CCAT2 CCAT1
27	glioblastoma	30.7	TUG1 MIR21 MIR137 MALAT1 HOTAIR H19
28	pre-eclampsia	30.6	TUG1 MALAT1 HOTAIR H19
29	leukemia, chronic myeloid	30.3	UCA1 MIR193A HOTAIR H19
30	lip and oral cavity cancer	11.5
31	squamous cell carcinoma, head and neck	11.2
32	leukoplakia	11.2
33	oral leukoplakia	11.1
34	head and neck cancer	11.1
35	lichen planus	11.0
36	oral lichen planus	10.9
37	oral submucous fibrosis	10.9
38	papilloma	10.9
39	conotruncal heart malformations	10.8
40	down syndrome	10.8
41	keratoacanthoma	10.7
42	oral cavity cancer	10.7
43	verrucous carcinoma	10.7
44	oculopharyngeal muscular dystrophy	10.7
45	mucositis	10.7
46	periodontitis	10.7
47	severe combined immunodeficiency	10.6
48	hypereosinophilic syndrome	10.6
49	b-cell lymphoma	10.6
50	renal cell carcinoma, nonpapillary	10.6	UCA1 TUG1 MIR21 MIR193A MIR100 MALAT1

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

Sources

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 2, Phase 3

15663-27-1

2767 5702198 441203

Docetaxel

Approved, Investigational

Phase 2, Phase 3

114977-28-5

148124

Fluorouracil

Approved

Phase 2, Phase 3

51-21-8

3385

Melatonin

Approved, Nutraceutical, Vet_approved

Phase 3

73-31-4

896

Antioxidants

Phase 3

Protective Agents

Phase 3

Antimetabolites

Phase 2, Phase 3

Immunosuppressive Agents

Phase 2, Phase 3

Immunologic Factors

Phase 2, Phase 3

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Cetuximab

Approved

Phase 2

205923-56-4

Raspberry

Approved

Phase 1, Phase 2

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Olaparib

Approved

Phase 1, Phase 2

763113-22-0

23725625

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Nimotuzumab

Investigational

Phase 2

780758-10-3

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 1, Phase 2

Pharmaceutical Solutions

Phase 1, Phase 2

Protein Kinase Inhibitors

Phase 2

Antirheumatic Agents

Phase 2

Cyclooxygenase Inhibitors

Phase 2

Cyclooxygenase 2 Inhibitors

Phase 2

Anti-Inflammatory Agents, Non-Steroidal

Phase 2

Analgesics, Non-Narcotic

Phase 2

Anti-Inflammatory Agents

Phase 2

Analgesics

Phase 2

Mitogens

Phase 2

Rivoceranib

Investigational

Phase 1

811803-05-1

11315474

Immune Checkpoint Inhibitors

Phase 1

Carbamide peroxide

Approved

124-43-6

Licorice

Approved

Early Phase 1

Phenol

Approved, Experimental

Early Phase 1

108-95-2

996

Capsaicin

Approved

404-86-4

1548943

Pembrolizumab

Approved

1374853-91-4

254741536

Dimenhydrinate

Approved

523-87-5

10660

Arginine

Approved, Investigational, Nutraceutical

74-79-3

6322

Phenethyl Isothiocyanate

Investigational

2257-09-2

16741

Antiviral Agents

Early Phase 1

Anti-Bacterial Agents

Early Phase 1

Antimalarials

Early Phase 1

Anti-Infective Agents

Complement System Proteins

Interventional clinical trials:

(show top 50) (show all 64)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC)	Completed	NCT04137627	Phase 3	Melatonin 20 MG Oral Capsule;Placebo oral capsule
2	Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma	Completed	NCT01542931	Phase 2, Phase 3	TPF induction chemotherapy
3	Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state)	Completed	NCT00964977	Phase 3
4	Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin Versus Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma	Recruiting	NCT05125055	Phase 2, Phase 3	Toripalimab (anti-programmed death-1 inhibitor);Albumin paclitaxel;Cisplatin;Docetaxel;5-Fluorouracil
5	Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer	Recruiting	NCT04333537	Phase 2, Phase 3	Imaging Agent
6	Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer	Unknown status	NCT02739204	Phase 2	Celecoxib
7	Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma	Completed	NCT03502148	Phase 1, Phase 2	PRV111 (Cisplatin Transmucosal System)
8	A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC)	Completed	NCT00933387	Phase 2	Cetuximab,Paclitaxel,Cisplatin
9	Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention	Completed	NCT01192204	Phase 1, Phase 2	10% FBR containing bioadhesive gel;placebo gel
10	Neoadjuvant Personalized Anti-PD-1 Therapy With Combination of Anti-VEGFR Therapy in Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Randomized Controlled Phase II Trial	Recruiting	NCT05069857	Phase 2	Camrelizumab (anti-PD-1 inhibitor);Apatinib (anti-VEGFR inhibitor)
11	A Phase II, Prospective, Single-center, Randomized, Controlled Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma	Recruiting	NCT04367909	Phase 2	Nimotuzumab;Docetaxel;Carboplatin
12	Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma	Recruiting	NCT04718415	Phase 2	sintilimab, paclitaxel, carboplatin
13	A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas	Recruiting	NCT03085147	Phase 1, Phase 2	Olaparib
14	Camrelizumab Plus Docetaxel and Cisplatin as First-line Therapy in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE): an Open-label, Single-arm, Phase II Trial	Recruiting	NCT05611463	Phase 2	Camrelizumab Plus Docetaxel and Cisplatin
15	Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Reduction of Cycles of Chemotherapy, as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma	Recruiting	NCT05098119	Phase 2	Sintilimab, Nab-paclitaxel, Carboplatin;Sintilimab
16	GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial	Recruiting	NCT02285530	Phase 2	TPF induction chemotherapy
17	A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma	Recruiting	NCT02285543	Phase 2	TPF induction chemotherapy
18	Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial	Recruiting	NCT02290145	Phase 2	TPF group
19	A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma	Active, not recruiting	NCT04649476	Phase 2	Camrelizumab;Camrelizumanb plus TPF
20	Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.	Active, not recruiting	NCT02748707	Phase 2	Arm1;Arm 2;Arm 3
21	Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma	Completed	NCT00009841	Phase 1	DC-cholesterol liposome
22	Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC): A Phase I Trial	Active, not recruiting	NCT04413214	Phase 1	Carrimycin
23	Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial	Active, not recruiting	NCT04473716	Phase 1	Toripalimab;Paclitaxcel;Cisplatin
24	Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial	Active, not recruiting	NCT04393506	Phase 1	Camrelizumab;Apatinib
25	Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma	Unknown status	NCT01987934
26	Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study	Unknown status	NCT03345966
27	The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw	Unknown status	NCT03418454
28	Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line	Unknown status	NCT03619304
29	Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma	Unknown status	NCT01587573
30	A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer.	Unknown status	NCT01772706
31	Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma-A Prospective Multicenter Randomized Controlled Study	Unknown status	NCT01334320
32	The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma	Unknown status	NCT01946230
33	Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line	Unknown status	NCT03292822	Early Phase 1	Paclitaxel
34	The Role of microRNA-29b in the Oral Squamous Cell Carcinoma	Unknown status	NCT02009852
35	Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma	Unknown status	NCT03877159
36	Myeloid-derived Suppressor Cells (MDSCs) Detection Before and After Beta-glucan Administration in Oral Squamous Cell Carcinoma Patients	Unknown status	NCT04387682
37	SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck	Unknown status	NCT00571883
38	The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma	Unknown status	NCT00173849
39	Verification of Saliva MMP-1 as a Strong Diagnostic Marker of Oral Cavity Cancer	Completed	NCT05049408
40	Fluorescent Visualization in Early Oral Cancer	Completed	NCT02306967
41	Molecular Mechanisms of Precancerous and Cancerous Lesions of the Oral Cavity	Completed	NCT03026361
42	Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma	Completed	NCT03554967
43	Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma?	Completed	NCT00693550
44	Modern Hybrid Imaging for Staging and Monitoring Patients With Oral Squamous Cell Carcinoma	Completed	NCT04280159
45	Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study)	Completed	NCT03109457
46	Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma.	Completed	NCT02323672
47	A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma	Completed	NCT01465776
48	Survival Analysis of Segmental Mandibulectomy With Immediate Vascularized Fibula Flap Reconstruction in Stage IV Oral Squamous Cell Carcinoma Patients	Completed	NCT04967638
49	A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer	Completed	NCT01314755
50	Ultrasound in Oral Tongue Cancer- Measurement of Depth of Invasion and Intraoperative Help in the Resection	Completed	NCT04059861

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Sources

Genetic Tests for Oral Squamous Cell Carcinoma

Sources

Anatomical Context for Oral Squamous Cell Carcinoma

Organs/tissues related to Oral Squamous Cell Carcinoma:

MalaCards : Lymph Node, Myeloid, Skin, Tongue, Bone Marrow, Bone, Endothelial

Sources

Publications for Oral Squamous Cell Carcinoma

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 12521)

#	Title	Authors	PMID	Year
1	Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. ⁶² ⁴⁶	Henson BJ...Gollin SM	19396866	2009
2	The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. ⁶² ⁴⁶	Yu T...Yi XZ	19435529	2009
3	Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. ⁶² ⁴⁶	Kozaki K...Inazawa J	18381414	2008
4	Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. ⁴⁶	Chang KW...Lin SC	18946016	2008
5	The role of circular RNAs in the pathophysiology of oral squamous cell carcinoma. ⁶²	Sufianov A...Beylerli O	36474750	2023
6	Chronic restraint stress promotes the tumorigenic potential of oral squamous cell carcinoma cells by reprogramming fatty acid metabolism via CXCL3 mediated Wnt/β-catenin pathway. ⁶²	Lou F...Jin X	36343679	2023
7	[Retracted] MicroRNA‑655 suppresses cell proliferation and invasion in oral squamous cell carcinoma by directly targeting metadherin and regulating the PTEN/AKT pathway. ⁶²	Wang Q...Ji H	36382654	2023
8	Evaluation of Immunoexpression of AJUBA Protein in Normal Oral Mucosa and Oral Squamous Cell Carcinoma. ⁶²	Desai P...Mane DR	36222508	2023
9	Mouse Models of Tumor Bone Metastasis and Invasion for Studying CCN Proteins. ⁶²	Shimo T...Sasaki A	36370362	2023
10	Notum leads to potential pro-survival of OSCC through crosstalk between Shh and Wnt/β-catenin signaling via p-GSK3β. ⁶²	Yang P...Li M	36280040	2022
11	Geniposide inhibits cell proliferation and migration in human oral squamous carcinoma cells via AMPK and JNK signaling pathways. ⁶²	Bai G...Zhao D	36382092	2022
12	Early-onset oral cancer as a clinical entity: aetiology and pathogenesis. ⁶²	Kolegova ES...Denisov EV	35487818	2022
13	Oncological outcomes of compartmental surgery and wide local excision in oral tongue and floor of the mouth cancer. ⁶²	Missale F...Piazza C	36306673	2022
14	Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment. ⁶²	Jehn P...Korn P	34609700	2022
15	Prognostic Relevance of Lymphatic Vessel Density in Squamous Cell Carcinomas of the Oral Cavity: A Systematic Review and Meta-Analysis. ⁶²	Tandon A...Kumar A	35904748	2022
16	Evaluation of Expression Of ADAM 10 as a Predictor of Lymph Node Metastasis in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. ⁶²	Jain R...Salunke M	35771404	2022
17	Significance of nuclear EGFR and ABCG2 expression in malignant transformation of oral potentially malignant disorders. ⁶²	Tarle M...Luksic I	36325600	2022
18	Prognostic impact of autoimmune disease in oral cavity squamous cell carcinoma. ⁶²	Pillai A...Patel SG	35870114	2022
19	Systemic conditions associated with increased risk to develop oral squamous cell carcinoma: Systematic review and meta-analysis. ⁶²	Dos Santos ES...Santos-Silva AR	36114663	2022
20	Combining radiation therapy with zoledronate for the treatment of osteo-invasive feline oral squamous cell carcinoma. ⁶²	Lundberg AP...Selting KA	35561080	2022
21	Effect of low-level light therapy before radiotherapy in oral squamous cell carcinoma: An in vitro study. ⁶²	Tabosa ATL...Guimaraes ALS	36001245	2022
22	Influence of tumor cell-derived TGF-β on macrophage phenotype and macrophage-mediated tumor cell invasion. ⁶²	Maldonado LAG...Rossa C	36343916	2022
23	Overexpression of gamma glutamyl hydrolase predicts extranodal extension in squamous cell carcinoma of the oral cavity. ⁶²	Burhanudin NA...Kallarakkal TG	36229363	2022
24	Variability in Depth of Invasion Measurements in Carcinomas of the Oral Cavity and the Effect on Pathologic Tumor Staging. ⁶²	Allen-Proctor MK...Griffith CC	35499641	2022
25	NEDD4L inhibits glycolysis and proliferation of cancer cells in oral squamous cell carcinoma by inducing ENO1 ubiquitination and degradation. ⁶²	Zhang G...Liu W	35316145	2022
26	An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma. ⁶²	Gohara S...Nakayama H	36381653	2022
27	The long non-coding RNA MEG3 inhibits oral squamous cell carcinoma progression via GATA3. ⁶²	Hu Y...Qiu Y	36468944	2022
28	Potential use of salivary mRNA-based biomarkers to predict oral squamous cell carcinoma. ⁶²	Tang KD...Punyadeera C	36274347	2022
29	Author Correction: Oral Squamous Cell Carcinoma Frequency in Young Patients from Referral Centers Around the World. ⁶²	Ferreira E Costa R...Fonseca FP	36239868	2022
30	MicroRNA-382-5p Promotes Oral Squamous Cell Carcinoma Development and Progression by Negatively Regulating PTEN Expression. ⁶²	Xu X...Luo J	36162436	2022
31	Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma. ⁶²	Nakagawa T...Aikawa T	35713706	2022
32	Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma. ⁶²	Li W...Mei Z	36444617	2022
33	MF-094 nanodelivery inhibits oral squamous cell carcinoma by targeting USP30. ⁶²	Zhang X...Liu L	36474192	2022
34	Circular RNA_0076977 contributes to oral squamous cell carcinoma progression through mediating microRNA-802 axis. ⁶²	Hei N...Jin L	36265392	2022
35	GATA6 regulates expression of annexin A10 (ANXA10) associated with epithelial-mesenchymal transition of oral squamous cell carcinoma. ⁶²	Takayama S...Uzawa N	36265396	2022
36	Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series. ⁶²	Naruse T...Umeda M	36311685	2022
37	IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma. ⁶²	Zhao M...Ding L	36463324	2022
38	Exosomal long noncoding RNAs MAGI2-AS3 and CCDC144NL-AS1 in oral squamous cell carcinoma development via the PI3K-AKT-mTOR signaling pathway. ⁶²	Li C...Huang X	36401978	2022
39	Comparison of tobacco and alcohol consumption in young and older patients with oral squamous cell carcinoma: a systematic review and meta-analysis. ⁶²	Batistella EA...De Luca Canto G	36131100	2022
40	Unfolded protein response is involved in the metabolic and apoptotic regulation of oral squamous cell carcinoma. ⁶²	Seo B...Rich AM	35791990	2022
41	N6-methyladenosine (m6A) reader IGF2BP2 stabilizes HK2 stability to accelerate the Warburg effect of oral squamous cell carcinoma progression. ⁶²	Xu K...Wen K	35763110	2022
42	CDH3 is associated with poor prognosis by promoting the malignancy and chemoresistance in oral squamous cell carcinoma. ⁶²	Wu T...Yang A	35305877	2022
43	Elucidating the genetic landscape of oral leukoplakia to predict malignant transformation. ⁶²	Wils LJ...Brakenhoff RH	36449687	2022
44	Development of Silver nanoparticles green-formulated by ‎Matricaria chamomilla as novel chemotherapeutic nanoformulation for the treatment of oral squamous cell carcinoma‎. ⁶²	Yang R...Gao Q	36397627	2022
45	Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target. ⁶²	Krishna A...Singh RK	35918593	2022
46	Effect of benzo[a]pyrene on proliferation and metastasis of oral squamous cell carcinoma cells: A transcriptome analysis based on RNA-seq. ⁶²	He H...Teng Y	35870112	2022
47	Therapeutic nature of microRNAs in Oral Squamous Cell Carcinoma (OSCC). ⁶²	Sekar D...Auxzilia Preethi K	36067592	2022
48	Spindle and kinetochore-associated complex 3 promotes cell growth via the PI3K/AKT/GSK3β and PI3K/AKT/FOXO1 pathways and is a potential prognostic biomarker for oral squamous cell carcinoma. ⁶²	Xu H...Han Z	36123287	2022
49	KDM3A promotes oral squamous cell carcinoma cell proliferation and invasion via H3K9me2 demethylation-activated DCLK1. ⁶²	Yang L...Yang Q	36094735	2022
50	Gene network analysis of the transcriptome impact of methylated microRNAs on oral squamous cell carcinoma. ⁶²	Avram EG...Sirbu IO	35951628	2022

Sources

Genes for Oral Squamous Cell Carcinoma

Genes related to Oral Squamous Cell Carcinoma (4 elite genes):

(show top 50) (show all 142)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR21	MicroRNA 21	RNA Gene	411.45	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18946016 19435529
2	MIR193A	MicroRNA 193a	RNA Gene	359.59	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
3	MIR100	MicroRNA 100	RNA Gene	355.38	Causal ⁴⁶ DISEASES inferred ¹⁴	19396866
4	MIR137	MicroRNA 137	RNA Gene	355.26	Causal ⁴⁶ DISEASES inferred ¹⁴	18381414
5	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	156.11	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23292713 24817925 25901533 (more) 26036760 29228709
6	UCA1	Urothelial Cancer Associated 1	RNA Gene	156.02	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23292713 24817925 26792186 (more) 27560546 29125238
7	HAS2-AS1	HAS2 Antisense RNA 1	RNA Gene	155.52	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28485478
8	LINC03033	Long Intergenic Non-Protein Coding RNA 3033	RNA Gene	155.42	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29346528
9	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	155.38	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	23292713 24817925
10	TUG1	Taurine Up-Regulated 1	Protein Coding	155.35	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28119088
11	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	155.21	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28413645
12	FOXCUT	FOXC1 Upstream Transcript	RNA Gene	155.19	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24889262
13	CEBPA-DT	CEBPA Divergent Transcript	RNA Gene	154.94	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29281558
14	LINC00668	Long Intergenic Non-Protein Coding RNA 668	RNA Gene	154.82	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28564590
15	CCAT2	Colon Cancer Associated Transcript 2	RNA Gene	154.45	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27220388 28671055
16	SOX21-AS1	SOX21 Antisense Divergent Transcript 1	RNA Gene	154.4	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27933111
17	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	153.67	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26522444 28926115
18	FTH1P3	Ferritin Heavy Chain 1 Pseudogene 3	Pseudogene	150	Experimental evidence: Regulation ³⁷	26276270 28093311
19	GTF2IRD2P1	GTF2I Repeat Domain Containing 2 Pseudogene 1	Pseudogene	150	Experimental evidence: Regulation ³⁷	26276270
20	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	150	Experimental evidence: Regulation ³⁷	29344674
21	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Expression ³⁷	23292713 28959364
22	MIR31	MicroRNA 31	RNA Gene	60.5	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
23	MIR9-1	MicroRNA 9-1	RNA Gene	60.24	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
24	MIR145	MicroRNA 145	RNA Gene	60.19	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19435529
25	MIR204	MicroRNA 204	RNA Gene	59.96	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
26	MIR139	MicroRNA 139	RNA Gene	59.64	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
27	MIR199A1	MicroRNA 199a-1	RNA Gene	59.54	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
28	MIR143	MicroRNA 143	RNA Gene	59.27	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19435529
29	MIR27B	MicroRNA 27b	RNA Gene	59.22	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
30	MIR126	MicroRNA 126	RNA Gene	59.05	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
31	MIR221	MicroRNA 221	RNA Gene	59	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19435529
32	MIR338	MicroRNA 338	RNA Gene	58.94	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
33	MIR372	MicroRNA 372	RNA Gene	58.92	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
34	MIR140	MicroRNA 140	RNA Gene	58.77	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
35	MIR330	MicroRNA 330	RNA Gene	58.76	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
36	MIR224	MicroRNA 224	RNA Gene	58.58	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
37	MIR296	MicroRNA 296	RNA Gene	58.51	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
38	MIR223	MicroRNA 223	RNA Gene	58.5	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
39	MIR23A	MicroRNA 23a	RNA Gene	58.47	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
40	MIR27A	MicroRNA 27a	RNA Gene	58.38	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
41	MIR23B	MicroRNA 23b	RNA Gene	58.36	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
42	MIR34C	MicroRNA 34c	RNA Gene	58.23	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
43	MIR148B	MicroRNA 148b	RNA Gene	57.9	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19435529
44	MIR26B	MicroRNA 26b	RNA Gene	57.9	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
45	MIR342	MicroRNA 342	RNA Gene	57.86	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
46	MIR30E	MicroRNA 30e	RNA Gene	57.65	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
47	MIRLET7E	MicroRNA Let-7e	RNA Gene	57.54	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
48	MIR340	MicroRNA 340	RNA Gene	57.07	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
49	MIR371A	MicroRNA 371a	RNA Gene	56.69	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18381414
50	MIR155	MicroRNA 155	RNA Gene	56.05	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18381414

Sources

Variations for Oral Squamous Cell Carcinoma

Cosmic variations for Oral Squamous Cell Carcinoma:

⁸ (show top 50) (show all 195)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM143943797	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	10
2	COSM142560281	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
3	COSM144087106	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	10
4	COSM144310203	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
5	COSM142837352	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
6	COSM145017657	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
7	COSM105620276	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
8	COSM143156843	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	10
9	COSM122271559	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	10
10	COSM106053189	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
11	COSM143370869	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
12	COSM111758576	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
13	COSM112253622	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
14	COSM93183630	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
15	COSM144013367	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.710G>A	p.R237Q	17:7674220-7674220	10
16	COSM144651115	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
17	COSM87898351	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	10
18	COSM121875983	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	10
19	COSM122734176	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	10
20	COSM133256111	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1040C>T	p.S347F	9:99146601-99146601	10
21	COSM97906895	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1016C>T	p.S339F	9:99146601-99146601	10
22	COSM135128838	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1259C>T	p.S420F	9:99146601-99146601	10
23	COSM97922732	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1247C>T	p.S416F	9:99146601-99146601	10
24	COSM84678061	SMO	skin,neck,carcinoma,squamous cell carcinoma	c.1103C>T	p.P368L	7:129206332-129206332	10
25	COSM98728167	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1384C>T	p.P462S	17:40356221-40356221	10
26	COSM107058787	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1093C>T	p.P365S	17:40356221-40356221	10
27	COSM98724263	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1432C>T	p.P478S	17:40356221-40356221	10
28	COSM86828717	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1384C>T	p.P462S	17:40356221-40356221	10
29	COSM98707797	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1369C>T	p.P457S	17:40356221-40356221	10
30	COSM94496058	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	10
31	COSM133940534	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	10
32	COSM107373333	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	10
33	COSM130526023	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	10
34	COSM96948694	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
35	COSM97161923	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
36	COSM96619514	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
37	COSM97161935	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10
38	COSM144156675	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.473G>A	p.G158E	20:42352227-42352227	10
39	COSM96619533	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10
40	COSM93273665	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10
41	COSM96721565	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
42	COSM96835332	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
43	COSM142597931	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.454C>T	p.S152L	20:42352239-42352239	10
44	COSM144156682	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.461C>T	p.S154L	20:42352239-42352239	10
45	COSM97061657	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
46	COSM96835350	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10
47	COSM96721578	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10
48	COSM96948708	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10
49	COSM93273656	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	10
50	COSM97061670	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	10

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

⁶ (show top 50) (show all 164)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	41848	10	24600000	38000000	Deletion		Oral squamous cell carcinoma
2	49706	11	110400000	121200000	Deletion		Oral squamous cell carcinoma
3	50988	11	121200000	130800000	Deletion		Oral squamous cell carcinoma
4	51497	11	12700000	16200000	Deletion		Oral squamous cell carcinoma
5	58782	11	69471367	69490165	Amplification	LTO1	Oral squamous cell carcinoma
6	74065	13	1	4500000	Deletion		Oral squamous cell carcinoma
7	74179	13	101700000	110300000	Deletion		Oral squamous cell carcinoma
8	75170	13	17900000	115169878	Noncopy numberrandom LOH		Oral squamous cell carcinoma
9	76133	13	27800000	55300000	Deletion		Oral squamous cell carcinoma
10	76134	13	27800000	87700000	Deletion		Oral squamous cell carcinoma
11	76220	13	28900000	40100000	Deletion		Oral squamous cell carcinoma
12	76534	13	32200000	40100000	Deletion		Oral squamous cell carcinoma
13	76709	13	35500000	40100000	Deletion		Oral squamous cell carcinoma
14	77109	13	40100000	59600000	Deletion		Oral squamous cell carcinoma
15	78640	13	55300000	73300000	Deletion		Oral squamous cell carcinoma
16	79281	13	68600000	87700000	Deletion		Oral squamous cell carcinoma
17	79539	13	73300000	79000000	Deletion		Oral squamous cell carcinoma
18	79879	13	79000000	87700000	Deletion		Oral squamous cell carcinoma
19	80342	13	90000000	98200000	Deletion		Oral squamous cell carcinoma
20	80629	13	95000000	110300000	Deletion		Oral squamous cell carcinoma
21	80632	13	95000000	115169878	Deletion		Oral squamous cell carcinoma
22	80634	13	95000000	98200000	Deletion		Oral squamous cell carcinoma
23	83034	14	19100000	33300000	Deletion		Oral squamous cell carcinoma
24	84231	14	24600000	33300000	Deletion		Oral squamous cell carcinoma
25	85052	14	37800000	50900000	Deletion		Oral squamous cell carcinoma
26	87452	14	73800000	79300000	Deletion		Oral squamous cell carcinoma
27	89133	15	1	19000000	Noncopy numberrandom LOH		Oral squamous cell carcinoma
28	90246	15	20700000	40100000	Deletion		Oral squamous cell carcinoma
29	91779	15	33600000	40100000	Deletion		Oral squamous cell carcinoma
30	91783	15	33600000	44800000	Deletion		Oral squamous cell carcinoma
31	92363	15	40100000	49500000	Deletion		Oral squamous cell carcinoma
32	92861	15	44800000	49500000	Deletion		Oral squamous cell carcinoma
33	95627	15	78300000	89100000	Deletion		Oral squamous cell carcinoma
34	95629	15	78300000	98500000	Deletion		Oral squamous cell carcinoma
35	106754	17	1	16000000	Deletion		Oral squamous cell carcinoma
36	106831	17	1	24000000	Noncopy numberrandom LOH		Oral squamous cell carcinoma
37	106907	17	1	81195210	Deletion		Oral squamous cell carcinoma
38	106970	17	10700000	50200000	Deletion		Oral squamous cell carcinoma
39	114590	17	50200000	70900000	Deletion		Oral squamous cell carcinoma
40	116098	17	62600000	70900000	Deletion		Oral squamous cell carcinoma
41	121461	18	43500000	53800000	Deletion		Oral squamous cell carcinoma
42	121864	18	48200000	53800000	Deletion		Oral squamous cell carcinoma
43	122810	18	61600000	73100000	Deletion		Oral squamous cell carcinoma
44	141367	2	209000000	221500000	Deletion		Oral squamous cell carcinoma
45	141699	2	215300000	221500000	Deletion		Oral squamous cell carcinoma
46	158362	21	31500000	35800000	Deletion		Oral squamous cell carcinoma
47	163225	22	25900000	37600000	Deletion		Oral squamous cell carcinoma
48	166065	3	1	16400000	Deletion		Oral squamous cell carcinoma
49	166126	3	1	8700000	Deletion		Oral squamous cell carcinoma
50	166139	3	1	91000000	Noncopy numberrandom LOH		Oral squamous cell carcinoma

Sources

Expression for Oral Squamous Cell Carcinoma

Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Sources

Pathways for Oral Squamous Cell Carcinoma

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	9.88	UCA1 MIR21

Sources

GO Terms for Oral Squamous Cell Carcinoma

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.28	NEAT1 MIR21 MIR137 MIR100 H19

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	9.65	NEAT1 MIR21 MIR193A MIR137 MIR100 H19
2	negative regulation of superoxide dismutase activity	GO:1901670	8.62	MIR21 H19

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.26	MIR21 MIR193A MIR137 MIR100
2	mRNA base-pairing translational repressor activity	GO:1903231	8.92	MIR21 MIR193A MIR137 MIR100